Irritable Bowel Syndrome News and Research RSS Feed - Irritable Bowel Syndrome News and Research

Irritable bowel syndrome (IBS) is a common disorder that affects the large intestine, often causing bouts of cramping, abdominal pain, bloating, diarrhea and constipation.

IBS is not curable but, in most cases, people learn to live with and control the condition by managing diet, lifestyle and stress levels. Medications to treat diarrhea, pain killers or drugs that relieve painful bowel spasms may also be used.

The cause of IBS is not yet clear but it is linked to changes in the way food is moved through the bowel. In healthy people, layers of muscle lining the intestinal wall contract and relax in a coordinated manner to move food from the stomach, through the colon and into the rectum. When an individual has IBS, however, the contractions are unusually strong and food is passed through the intestine too quickly which leads to diarrhea and a build up of gas.

Triggers for IBS range from pressure on the intestines to certain foods such as chocolate or carbonated drinks, hormonal changes such as during the menstrual cycle and emotional changes such as an increase in stress.

IBS can be painful and debilitating if not treated appropriately, negatively impacting on a person’s quality of life. However, with appropriate treatment individuals with IBS should be able to live a full and active life.
Learning role of immune-system cells in digestive tracts may lead to new treatments for IBS

Learning role of immune-system cells in digestive tracts may lead to new treatments for IBS

Learning the role of immune-system cells in healthy digestive tracts and how they interact with neighboring nerve cells may lead to new treatments for irritable bowel syndrome (IBS). [More]
Role of immune system cells in healthy digestive tracts may lead to new treatments for IBS

Role of immune system cells in healthy digestive tracts may lead to new treatments for IBS

Learning the role of immune system cells in healthy digestive tracts and how they interact with neighboring nerve cells may lead to new treatments for irritable bowel syndrome (IBS). [More]
Independent testing organization confirms VSL#3 formulation as probiotic product

Independent testing organization confirms VSL#3 formulation as probiotic product

Probiotics have gained in popularity in recent years and consumers now have many to choose from. However, only 14 of 19 successfully tested through Consumer Lab's quality certification program probiotics. [More]
Researchers develop new "nanojuice" to help doctors better identify human gut

Researchers develop new "nanojuice" to help doctors better identify human gut

Located deep in the human gut, the small intestine is not easy to examine. X-rays, MRIs and ultrasound images provide snapshots but each suffers limitations. Help is on the way. [More]
Treating ulcerative colitis and Crohn’s disease: an interview with Dr. Stephen Hanauer, Medical Director, Digestive Health Center, Northwestern University Feinberg School of Medicine

Treating ulcerative colitis and Crohn’s disease: an interview with Dr. Stephen Hanauer, Medical Director, Digestive Health Center, Northwestern University Feinberg School of Medicine

Ulcerative colitis and Crohn’s disease are idiopathic (we don’t know the cause) inflammatory diseases (IBD) of the colon and/or small bowel. They are chronic in that we do not have a medical cure and are differentiated from IBS (irritable bowel syndrome) by inflammation that causes ulcerations of the GI tract. [More]
Forest Laboratories completes acquisition of Furiex Pharmaceuticals

Forest Laboratories completes acquisition of Furiex Pharmaceuticals

Actavis plc today announced that its subsidiary Forest Laboratories, LLC has successfully completed its acquisition of Furiex Pharmaceuticals, Inc. in an all-cash transaction valued at approximately $1.1 billion, and up to approximately $360 million in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval. [More]
Synthetic Biologics supports SYN-004 C.difficile preventative program with formation of Clinical Advisory Board

Synthetic Biologics supports SYN-004 C.difficile preventative program with formation of Clinical Advisory Board

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, announced today the formation of a Clinical Advisory Board (CAB) to support development of SYN-004, the Company's lead anti-infective product candidate for the prevention of the devastating effects of Clostridium difficile (C. difficile) [More]
Complementary medicines: an interview with Associate Professor Evelin Tiralongo, Griffith University

Complementary medicines: an interview with Associate Professor Evelin Tiralongo, Griffith University

Complementary medicines are generally being defined as medicines which are non-mainstream medicines and are mostly given together with conventional medicines. [More]
Synthetic, Enterome partner to study effects of beta-lactam antibiotics on gastrointestinal microflora

Synthetic, Enterome partner to study effects of beta-lactam antibiotics on gastrointestinal microflora

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, and Enterome Bioscience SA, a pioneer in the development of innovative disease management solutions based on a deep understanding of the gut microbiome, today announced that they have entered into an agreement to conduct metagenomic research on the effects of beta-lactam antibiotics on the gastrointestinal microflora (microbiome) of human patients. [More]
Squatty Potty toilet stool improves severity of constipation symptoms

Squatty Potty toilet stool improves severity of constipation symptoms

When used as a treatment, the original Squatty Potty (www.squattypotty.com) toilet stool significantly improves the severity of constipation symptoms within one month of use among 84 percent of the participants of a recently released scientific study. [More]
Cell Science Systems launches new blood test profile for GI disorders

Cell Science Systems launches new blood test profile for GI disorders

Distinguishing the cause of gut disorders can be complicated. Therefore, Cell Science Systems, Corp. today announced the launch of a new test to help clinicians reach a diagnosis; and, suggest dietary strategies to improve whatever gut malady a person may have. [More]
University of Missouri to award honorary degree to Chairman and CEO of Synergy Pharmaceuticals

University of Missouri to award honorary degree to Chairman and CEO of Synergy Pharmaceuticals

Synergy Pharmaceuticals Inc., today announced its Chairman and Chief Executive Officer, Dr. Gary S. Jacob, will be recognized and awarded with the honorary degree, Doctor of Science Honoris Causa, from his alma mater, the University of Missouri - St. Louis, at a commencement ceremony this Saturday, May 17, 2014. [More]
Olympus launches next-generation ENDOCAPSULE 10 System for capsule endoscopy procedures

Olympus launches next-generation ENDOCAPSULE 10 System for capsule endoscopy procedures

Olympus, a precision technology leader in designing and delivering innovative solutions in Medical and Surgical Products, among other core businesses, announced today the commercial availability of its 510(k) cleared, next-generation ENDOCAPSULE 10 System for small bowel capsule endoscopy procedures. [More]
Vibrating oral capsule for chronic constipation shows positive results

Vibrating oral capsule for chronic constipation shows positive results

An oral capsule that vibrates as it moves through the digestive tract has shown notable promise as a non-pharmacological treatment for constipation, according to new research presented today at Digestive Disease Week- (DDW). [More]
Synergy reports positive top-line results from plecanatide phase 2b study in patients with IBS-C

Synergy reports positive top-line results from plecanatide phase 2b study in patients with IBS-C

Synergy Pharmaceuticals Inc. today announced positive top-line results from a phase 2b dose-ranging study assessing plecanatide's safety and efficacy in 424 patients with irritable bowel syndrome with constipation (IBS-C). [More]
Forest Laboratories enters into definitive agreement to acquire Furiex

Forest Laboratories enters into definitive agreement to acquire Furiex

Forest Laboratories, Inc. nd Furiex Pharmaceuticals, Inc. today announced that Forest has entered into a definitive agreement to acquire Furiex, a drug development collaboration company, for $95 per share, or approximately $1.1 billion in cash, and up to $30 per share (approximately $360 million in aggregate) in a Contingent Value Right (CVR) that may be payable based on the status of eluxadoline, Furiex's lead product, as a controlled drug following approval. [More]
Reduced exposure to microbes triggers chronic inflammation

Reduced exposure to microbes triggers chronic inflammation

The greater prevalence of asthma, allergies and other chronic inflammatory disorders among people of lower socioeconomic status might be due in part to their reduced exposure to the microbes that thrive in rural environments, according to a new scientific paper. [More]
Nearly 179 million cases of acute diarrhea occur each year in the U.S.

Nearly 179 million cases of acute diarrhea occur each year in the U.S.

In the United States, approximately 179 million cases of acute diarrhea occur each year, and most of those cases are entirely preventable, a researcher from The University of Texas Health Science Center at Houston concluded in a New England Journal of Medicine review article. [More]
Prevalence of celiac disease on the rise among children with irritable bowel syndrome

Prevalence of celiac disease on the rise among children with irritable bowel syndrome

There appears to be an increased prevalence of celiac disease among children with irritable bowel syndrome (IBS). [More]
Study sheds light on factors that lead to development of rare condition affecting inner ear

Study sheds light on factors that lead to development of rare condition affecting inner ear

A new study has shed light on the factors likely to lead to the development of a rare condition affecting the inner ear. [More]